Oral presentation highlights investigator case reports showing early signs of activity of Tedopi® in patients with non-small cell lung cancer in third-line treatment after checkpoint inhibitor failure Poster presentation shows new preclinical mechanistic data of BI...
Massive Bio, Inc., a leader in providing simplified and affordable access to clinical trials and precision oncology to cancer patients treated at community-based oncology practices, announced today that its Trials-in-Progress poster titled “SYNERGY-AI: Artificial...
VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”) today announced that it has added to its extensive clinical trial program with the execution of a non-binding Memorandum of Understanding, through its wholly-owned subsidiary, Belgian Volition SPRL, to...
New Protocol Creator Software Brings Treatments to Market Faster Cognizant (Nasdaq: CTSH) has introduced Cognizant Protocol Creator, a SaaS collaboration product that automates the development of clinical trial protocol documentation. A first for the life sciences...
Investigational vaccine designed to provide broad, durable protection from flu. The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in...
Glioblastoma is the most aggressive type of primary brain cancer, one with a prognosis of 11-15 months with standard treatment. Results from a phase 1bclinical trial of a new experimental glioblastoma vaccine developed by Jefferson Health and Imvax, show the treatment...
Email
Text